Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (968)	7/16/1997 12:19:00 PM
From: Stefan Sarafianos	of 6136

Peter, I disagree with your first conclusion: "If you start with any of the other PI's and become resistant (which might happen even if you maintain good viral suppression) you will likely also be resistant to Viracept." -Ron Swanstrom's work did not include Viracept (nelfinavir). Furthermore, Winters et al. presented early results of a combination of in vitro and in vivo studies (Florida meeting) where there is some evidence that: -8 out of 9 sequinavir-treated patients do not have the 90 mutation, which would suggest resistance to nelfinavir. -However, in vitro susceptibility testing showed that isolates from some sequinavir-treated patients already had reduced susceptibility to nelfinavir and/or indinavir prior to treatment with these inhibitors. As I do not own any AGPH or MRK stock my perspective is probably different than most of the people tha post here. Nevertheless, my conclusions are mostly similar to yours and others in this discussion and I eagerly anticipate solid results about PIs. (By the way, the results I quote were not from Agouron's or Merck's scientists but from researchers at Stanford. Stefan

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next